US 6,982,084 B2
Prevention and treatment of amyloidogenic disease
Dale B. Schenk, Burlingame, Calif. (US)
Assigned to NeuraLab Limited, (Bermuda)
Filed on Mar. 31, 2004, as Appl. No. 10/815,404.
Application 09/723927 is a division of application No. 09/201430, filed on Nov. 30, 1998, granted, now 6,787,523.
Application 10/815404 is a continuation of application No. 09/723927, filed on Nov. 28, 2000, granted, now 6,787,138.
Claims priority of provisional application 60/080970, filed on Apr. 07, 1998.
Claims priority of provisional application 60/067740, filed on Dec. 02, 1997.
Prior Publication US 2005/0031629 A1, Feb. 10, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01)
U.S. Cl. 424—185.1 34 Claims
 
1. A pharmaceutical composition comprising an immunogenic Aβ fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the Aβ fragment.